The relation of esophagogastroduodenoscopy time and novel upper gastrointestinal quality measures.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
pubmed:
29
4
2022
medline:
7
6
2022
entrez:
28
4
2022
Statut:
ppublish
Résumé
Various measures of esophagogastroduodenoscopy (EGD) quality have been proposed so far and the examination time was one of the first. The aim of the study was to compare the procedure time with novel novel quality measures - composite detection rate (CDR) and endoscopist biopsy rate (EBR). It was prospective observational study. A total of 880 diagnostic EGDs conducted from 01.2019 to 07.2019 have been enrolled in the study. Median EGD time was 4.2 min. Procedures of longer duration were marked with higher CDR (26.3% vs. 11.8%; P < 0.0001), higher EBR (44.9% vs. 12.3%; P < 0.0001), and better upper gastrointestinal neoplasm (UGN) detection (1.8% vs. 0%; P = 0.004) in comparison with procedures of shorter duration. The procedures were divided into 4 groups based on the time quartiles (group 1 <3.3 min; group 2 3.3-4.2 min; group 3 4.2-5.3 min; group 4 >5.3 min). The odds ratios of groups 2, 3, and 4 for biopsy rate were 2.42 (95% CI, 1.33-4.55), 4.33 (95% CI, 2.46-7.94), and 5.51 (95% CI, 3.18-10.03), respectively, in comparison with group 1. The odds ratios of groups 2, 3, and 4 for CDR were 3.18 (95% CI, 2.03-4.97), 5.46 (95% CI, 3.51-8.50), and 23.44 (95% CI, 14.3-38.4), respectively, in comparison with group 1. The procedure time is related to novel metrics - CDR and EBR. It is also related to UGN. Based on our findings it could be concluded that EGD should not last less than 4.2 min.
Identifiants
pubmed: 35482906
doi: 10.1097/MEG.0000000000002385
pii: 00042737-202207000-00006
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
763-768Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Park WG, Shaheen NJ, Cohen J, Pike IM, Adler DG, Inadomi JM, et al. Quality indicators for EGD. Gastrointest Endosc. 2015; 81:17–30.
Min JK, Cha JM, Kwak MS, Yoon JY, Jung Y, Shin JE, Yang HJ. Quality indicators and outcome measures of endoscopy in the National Cancer Screening Program. Yonsei Med J. 2019; 60:1054–1060.
Beg S, Ragunath K, Wyman A, Banks M, Trudgill N, Pritchard DM, et al. Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS). Gut. 2017; 66:1886–1899.
Bisschops R, Areia M, Coron E, Dobru D, Kaskas B, Kuvaev R, et al. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy. 2016; 48:843–864.
Romańczyk M, Ostrowski B, Marek T, Romańczyk T, Błaszczyńska M, Budzyń K, et al. Composite detection rate as an upper gastrointestinal endoscopy quality measure correlating with detection of neoplasia. J Gastroenterol. 2021; 56:651–658.
Kaminski MF, Thomas-Gibson S, Bugajski M, Bretthauer M, Rees CJ, Dekker E, et al. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) quality improvement initiative. United European Gastroenterol J. 2017; 5:309–334.
Barclay RL, Vicari JJ, Doughty AS, Johanson JF, Greenlaw RL. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med. 2006; 355:2533–2541.
Shaukat A, Rector TS, Church TR, Lederle FA, Kim AS, Rank JM, Allen JI. Longer withdrawal time is associated with a reduced incidence of interval cancer after screening colonoscopy. Gastroenterology. 2015; 149:952–957.
Teh JL, Tan JR, Lau LJ, Saxena N, Salim A, Tay A, et al. Longer examination time improves detection of gastric cancer during diagnostic upper gastrointestinal endoscopy. Clin Gastroenterol Hepatol. 2015; 13:480–487.e2.
Park JM, Huo SM, Lee HH, Lee BI, Song HJ, Choi MG. Longer observation time increases proportion of neoplasms detected by esophagogastroduodenoscopy. Gastroenterology. 2017; 153:460–469.e1.
Kawamura T, Wada H, Sakiyama N, Ueda Y, Shirakawa A, Okada Y, et al. Examination time as a quality indicator of screening upper gastrointestinal endoscopy for asymptomatic examinees. Dig Endosc. 2017; 29:569–575.
Yoshimizu S, Hirasawa T, Horiuchi Y, Omae M, Ishiyama A, Yoshio T, et al. Differences in upper gastrointestinal neoplasm detection rates based on inspection time and esophagogastroduodenoscopy training. Endosc Int Open. 2018; 6:E1190–E1197.
Januszewicz W, Wieszczy P, Bialek A, Karpinska K, Szlak J, Szymonik J, et al. Endoscopist biopsy rate as a quality indicator for outpatient gastroscopy: a multicenter cohort study with validation. Gastrointest Endosc. 2019; 89:1141–1149.
Weusten B, Bisschops R, Coron E, Dinis-Ribeiro M, Dumonceau JM, Esteban JM, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy. 2017; 49:191–198.
Rodríguez de Santiago E, Hernanz N, Marcos-Prieto HM, De-Jorge-Turrión MÁ, Barreiro-Alonso E, Rodríguez-Escaja C, et al. Rate of missed oesophageal cancer at routine endoscopy and survival outcomes: a multicentric cohort study. United Eur Gastroenterol J. 2019; 7:189–198.
Pimenta-Melo AR, Monteiro-Soares M, Libânio D, Dinis-Ribeiro M. Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2016; 28:1041–1049.
Gupta N, Gaddam S, Wani SB, Bansal A, Rastogi A, Sharma P. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc. 2012; 76:531–538.
Park JM, Lim CH, Cho YK, Lee BI, Cho YS, Song HJ, Choi MG. The effect of photo-documentation of the ampulla on neoplasm detection rate during esophagogastroduodenoscopy. Endoscopy. 2019; 51:115–124.
Park CH, Kim B, Chung H, Lee H, Park JC, Shin SK, et al. Endoscopic quality indicators for esophagogastroduodenoscopy in gastric cancer screening. Dig Dis Sci. 2015; 60:38–46.
Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019; 51:365–388.